Baxter International Inc. (NYSE:BAX) Faces Mixed Financial Performance Amidst Market Challenges

Font: Financial Modeling Prep  • Oct 30, 2025

• Baxter International Inc. (NYSE:BAX) surpasses third-quarter adjusted EPS estimates but lowers its 2025 guidance, impacting investor sentiment.
• Despite a 14.73% potential upside from Stifel Nicolaus's price target, BAX experiences a significant stock price drop, reaching a 52-week low.
• Sales in the Medical Products and Therapies segment see a slight decline, attributed to reduced sales in the Infusion Therapies and Technologies division.

Baxter International Inc. (NYSE:BAX) is a global healthcare company that provides a broad portfolio of essential medical products, including devices, pharmaceuticals, and biotechnology. The company operates in various segments, with a focus on Medical Products and Therapies. BAX faces competition from other healthcare giants like Johnson & Johnson and Medtronic.

On October 30, 2025, Stifel Nicolaus set a price target of $22 for BAX, while the stock was priced at $19.18. This target suggests a potential upside of approximately 14.73%. Despite this optimistic outlook, BAX has faced challenges, including a significant drop in its stock price, reaching a 52-week low.

Baxter's recent financial performance shows mixed results. The company reported a third-quarter adjusted EPS of 69 cents, surpassing both management's guidance of 58-62 cents and Wall Street's estimate of 60 cents. However, the company's decision to lower its 2025 guidance has impacted investor sentiment.

Baxter's sales for the third quarter were $2.84 billion, a 5% increase year-over-year on a reported basis and a 2% increase on an operational basis. This closely aligns with the consensus of $2.88 billion. However, the management had anticipated higher growth, which may have contributed to the stock's decline.

The Medical Products and Therapies segment reported sales of approximately $1.33 billion, a 1% decline on both a reported and operational basis. This decline was mainly due to reduced sales in the Infusion Therapies and Technologies division, although strong global demand for other products partially offset this.